Department of Neurologic Surgery, Mayo Clinic, Jacksonville, FL.
Department of Neurology, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2018 Apr;93(4):523-538. doi: 10.1016/j.mayocp.2018.02.013.
Acute ischemic stroke (AIS) is among the leading causes of death and long-term disability. Intravenous tissue plasminogen activator has been the mainstay of acute therapy. Recently, several prospective randomized trials documented the value of endovascular revascularization in selected patients with large-vessel occlusion within the anterior circulation. This finding has led to a paradigm shift in the management of AIS, including wide adoption of noninvasive neuroimaging to assess vessel patency and tissue viability, with the supplemental and independent use of intravenous tissue plasminogen activator to improve clinical outcomes. In this article, we review the landmark studies on management of AIS and the current position on the diagnosis and management of AIS. The review also highlights the importance of early stabilization and prompt initiation of therapeutic interventions before, during, and after the diagnosis of AIS within and outside of the hospital.
急性缺血性脑卒中(AIS)是导致死亡和长期残疾的主要原因之一。静脉注射组织型纤溶酶原激活剂一直是急性治疗的主要方法。最近,几项前瞻性随机试验证明了血管内再通治疗在前循环大血管闭塞患者中的价值。这一发现导致了 AIS 管理模式的转变,包括广泛采用无创神经影像学来评估血管通畅性和组织活力,并补充和独立使用静脉注射组织型纤溶酶原激活剂来改善临床结局。本文回顾了 AIS 管理的重要研究,并介绍了目前 AIS 的诊断和管理的立场。本文还强调了在医院内外诊断 AIS 之前、期间和之后,早期稳定和及时开始治疗干预的重要性。